| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Rapamycin | GDSC1000 | pan-cancer | AAC | 0.063 | 0.2 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | A-804598 | CTRPv2 | pan-cancer | AAC | 0.059 | 0.2 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | -0.041 | 0.2 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | FTI-277 | GDSC1000 | pan-cancer | AAC | 0.04 | 0.2 |